Bargains Coming to Belmont, NH HARRISBURG, Pa. , July 17, 2025 /PRNewswire/ -- Ollie's Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) today celebrates the Grand Opening of its 600th store in Belmont and expansion into New Hampshire, its 34th state.

Permian completed a deal valued at approximately $608 million, which represents an increase of 13,320 net acres and 8,700 net royalty acres in New Mexico. Permian maintains a fossil fuel development presence in the Delaware Basin, with a total of 450,000 net working acres in its portfolio, equivalent to 370 MBOE/d of production. The company shows an EBITDA margin of over 75% and a RoCE of 14.30%.

SLB's stock (NYSE: SLB) is scheduled to announce its fiscal second-quarter earnings on Friday, July 18, 2025. Analysts forecast that the firm will disclose earnings of $0.75 per share on $8.51 billion in revenue.

ADTRAN Holdings (ADTN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

I am bullish on SNDK due to its strong position in a supply-constrained NAND market, supporting higher prices and earnings growth. Sandisk benefits from disciplined industry supply, AI-driven enterprise SSD demand, and a PC upgrade cycle, all fueling long-term revenue growth. Valuation is attractive, with potential for 24% upside as SNDK's revenue and margins expand, aligning with industry peers' multiples.

EPI, which weighs its Indian portfolio based on earnings power, has underperformed other EMs and global markets by a significant margin since we last covered it in November 2024. We have a problem with EPI's flawed methodology, high expense ratio, and inconsistent dividends, but if one may overlook these issues, there are now good enough reasons to turn positive. India's economic growth is accelerating, inflation is at a 6-year low, and the prospect of further rate cuts is picking up, creating a favorable backdrop for Indian equities.

New York, NY--(BUSINESS WIRE)--Gannett Co., Inc. (“Gannett”) (NYSE: GCI) announced today that it will release its second quarter 2025 financial results on Thursday, July 31, 2025, prior to the opening of the New York Stock Exchange. Management will host a conference call on Thursday, July 31, 2025 at 8:30 A.M. Eastern Time to review the financial and operating results for the period. A copy of the earnings release will be posted to the Investor Relations section of Gannett's website, investors.

Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26 Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increase ABBOTT PARK, Ill., July 17, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2025.

Revenues of $4.5 billion (flat as reported, -3% constant currency (CC), -1% organic CC) Latin America and Asia Pacific continued to experience good demand while demand in Europe and North America saw stabilizing trends in many markets during the quarter Manpower and Talent Solutions brands crossed back over to revenue growth in the quarter while Experis experienced declines on sluggish professional staffing demand Gross profit margin of 16.9% reflects a slight decrease from the previous quarter reflecting business mix changes impacting staffing while permanent recruitment activity levels remained stable SG&A declined year over year with additional restructuring actions taken in …

Valour Launches First Products on SIX Swiss Exchange: Valour has officially entered the Swiss market with the listing of two staking ETPs—1Valour Hedera (HBAR) and 1Valour Internet Computer (ICP)—on the SIX Swiss Exchange. Access to Native Yield Through Regulated ETPs: Both products offer secure, transparent, and regulated exposure to HBAR and ICP, while integrating native staking rewards directly into their structure.

PSFF is a Buy for investors prioritizing downside protection over maximum returns, especially those who prefer not to pick individual buffer ETFs. Buffer ETFs offer a defined balance of capped upside and downside protection, making them ideal for de-risking large or mature portfolios. PSFF consistently delivers lower risk and some upside, justifying its lower returns versus the S&P 500, as shown by strong risk-adjusted metrics.

Alcoa's Q2 FY2025 results showed revenue beat, but significant EPS decline due to lower alumina prices and sharply higher U.S. Section 232 tariffs. The primary issue is the massive impact of U.S. tariffs, which are expected to surge from a $95 million cost in Q2 to $215 million in Q3. The doubling of Section 232 tariffs to 50% will likely cause margin leakage and demand disruptions, posing long-term threats to Alcoa's U.S. market share.

I am upgrading PNC Financial from 'hold' to 'buy', due to strong Q2 earnings, robust loan growth, and improved asset quality. PNC raised its net interest income and loan growth guidance for FY 2025, reflecting higher commercial loan utilization and resilient credit quality. Despite shares now being fairly valued after a 30% rally, PNC's fundamentals and capital efficiency justify its current valuation, versus peers.

Ardent Health faces significant legislative risks, due to Medicaid and Medicare cuts, causing uncertainty and a recent downgrade, but much of this is priced in. Despite headwinds, Ardent Health demonstrates strong revenue and profitability growth, low leverage, and trades at compellingly cheap valuations, versus peers. Management projects continued growth for 2025, with revenue and EBITDA expected to rise, supported by higher-margin service expansions and acquisitions.

GREENWOOD VILLAGE, Colo., July 17, 2025 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced the Company will release its second quarter 2025 financial results and file its Quarterly Report on Form 10-Q for the period ended June 30, 2025, after market close on Monday, August 11, 2025. A conference call to discuss the Company's financial performance is scheduled for Tuesday, August 12, 2025, at 8:30 a.m. Eastern Time.

WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call.

LOUISVILLE, Ky., July 17, 2025 (GLOBE NEWSWIRE) -- Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today announced that it is has been awarded the prestigious Raymond James Community Bankers Cup for its performance in 2024.

Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET

This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has received approval from the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) to commence EMBRACE, the second pivotal study in PARADIGM, the Company's Phase 3 multinational program evaluating CYB0.